天津发展附属力生制药完成股份回购及采纳股票激励计划

智通财经2025-02-06

智通财经APP讯，天津发展(00882)发布公告，有关其间接非全资附属公司天津力生制药股份有限公司(力生制药)采纳股份回购方案及股票激励计划。于股份回购方案获采纳后，力生制药通过于深圳证券交易所以集中竞价交易方式，自2024年12月25日至2025年1月9日，按力生制药股份当时市价(其最高及最低回购价格分别为每股人民币18.50元及人民币17.28元)回购合共721万股其普通股股份，占其已发行股本...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2509325069?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-06 06:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2509325069","market":"hk","top_or_hot":-1,"title":"天津发展附属力生制药完成股份回购及采纳股票激励计划","media":"智通财经","content":"<div>\n<p>智通财经APP讯，天津发展(00882)发布公告，有关其间接非全资附属公司天津力生制药股份有限公司(力生制药)采纳股份回购方案及股票激励计划。于股份回购方案获采纳后，力生制药通过于深圳证券交易所以集中竞价交易方式，自2024年12月25日至2025年1月9日，按力生制药股份当时市价(其最高及最低回购价格分别为每股人民币18.50元及人民币17.28元)回购合共721万股其普通股股份，占其已发行股本...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206063007987bc7af&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天津发展附属力生制药完成股份回购及采纳股票激励计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天津发展附属力生制药完成股份回购及采纳股票激励计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-06 06:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206063007987bc7af&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，天津发展(00882)发布公告，有关其间接非全资附属公司天津力生制药股份有限公司(力生制药)采纳股份回购方案及股票激励计划。于股份回购方案获采纳后，力生制药通过于深圳证券交易所以集中竞价交易方式，自2024年12月25日至2025年1月9日，按力生制药股份当时市价(其最高及最低回购价格分别为每股人民币18.50元及人民币17.28元)回购合共721万股其普通股股份，占其已发行股本...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206063007987bc7af&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00882","symbol_name":"天津发展","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206063007987bc7af&s=b","article_id":"2509325069","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206063007987bc7af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2509325069","pubTimestamp":1738794461,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP讯，天津发展 发布公告，有关其间接非全资附属公司天津生制药股份有限公司采纳股份回购方案及股票激励计划。721万股回购股份将悉数用作股票激励计划下授予激励对象的限制性股份，故力生制药将不会就股票激励计划发行任何新股份。力生制药采纳股票激励计划有关批准股票激励计划的决议案已于2025年2月5日获力生制药股东于其股东大会上正式通过。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00882":"天津发展","BK1232":"复合型公用事业"},"translate_title":"Lisheng Pharmaceutical, a subsidiary of Tianjin Development, completed share repurchase and adopted share incentive plan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00882":1},"content_text":"智通财经APP讯，天津发展(00882)发布公告，有关其间接非全资附属公司天津力生制药股份有限公司(力生制药)采纳股份回购方案及股票激励计划。于股份回购方案获采纳后，力生制药通过于深圳证券交易所以集中竞价交易方式，自2024年12月25日至2025年1月9日，按力生制药股份当时市价(其最高及最低回购价格分别为每股人民币18.50元及人民币17.28元)回购合共721万股其普通股股份，占其已发行股本约2.80%，总金额为人民币1.29亿元，而回购价格并无超过力生制药每股人民币21.22元的上限价格。因此，该股份回购方案已获全面实施。721万股回购股份将悉数用作股票激励计划下授予激励对象的限制性股份，故力生制药将不会就股票激励计划发行任何新股份。力生制药采纳股票激励计划有关批准股票激励计划的决议案已于2025年2月5日获力生制药股东于其股东大会上正式通过。因此，股票激励计划已获正式采纳，并将由力生制药根据该公告先前所述的主要条款实施。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,buyback","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509325069","isCrawlerRequest":true}